What were the trends that drove the biopharma and drug delivery markets in 2018?
Many of 2018’s key trends revolved around increasing regulatory requirements. However, as the market continues to move toward more personalized medicine, such as cell and gene therapies, the overall cost of health care is a driving factor. While the majority of large patient population indications, including diabetes and rheumatoid arthritis, have available biologic treatments, there are exceptions. Those suffering from Alzheimer’s or Parkinson’s still need a breakthrough drug. Currently, the pipeline consists mostly of smaller patient population molecules or orphan drugs, which means that the treatments, while needed, are extremely expensive.
